Corrigendum: Unraveling the interplay between norovirus infection, gut microbiota, and novel antiviral approaches: a comprehensive review

Front Microbiol. 2023 Dec 1:14:1324539. doi: 10.3389/fmicb.2023.1324539. eCollection 2023.

Geng-Hao Bai^#¹, Meng-Chen Tsai^#², Sheng-Chieh Lin^{3

4}, Yi-Hsiang Hsu^{5

6}, Shih-Yen Chen^{3

7

8}

¹ Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
² Department of General Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
³ Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁴ Department of Pediatrics, Division of Allergy, Asthma and Immunology, Shuang Ho Hospital, New Taipei, Taiwan.
⁵ Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
⁶ Broad Institute of MIT and Harvard, Cambridge, MA, United States.
⁷ Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, Shuang Ho Hospital, New Taipei, Taiwan.
⁸ TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fmicb.2023.1212582.].

Keywords: human intestinal enteroid; microbiota; norovirus; norovirus vaccine; probiotics.

The study was supported by grants from NSTC 112-2622-E-038-004, Taiwan.